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OBJECTIVE: To determine the cost-effectiveness of
standard strategy (interferon alpha) versus Cladribine (2-
chlorodeoxyadenosine) and Cladribine with interferon alpha
treatment for patients with hairy cell leukemia. METHODS: A
cost-effectiveness analysis was performed. Efﬁcacy of standard
treatment strategy, Cladribine and Cladribine with interferon
treatment, was estimated from a previous clinical trial held in
Moscow HRC RAMS. A total of 160 patients entered the trial.
Three group patients with hairy cell leukemia were assigned to
receive: 1st group—interferon alpha (3 million units thrice a
week), 2nd group—Cladribine (0.1 mg/kg daily as a continuous
intravenous infusion over seven days), 3rd group received
Cladribine with interferon alpha. Direct medical costs (cost of
drug administration, resource utilization, duration of hospital-
ization) were estimated. Achievement of remission was used as
effectiveness. Unit costs were based on detailed data from the
Moscow Medical Sechenov Academy. The rate of exchange was
24.4 rubles for USD$1. RESULTS: direct medical costs were
RUR93 477 for group 1 (C1), RUR91756 for group 2 (C2) and
RUR40 436 for group 3 (C3). Achievement of remission = 70.0
% (E1), 99.0% (E2), 99.0% (E3), for each group respectively.
The ﬁnal calculation of cost / effectiveness ratio (CER) was:
CER1 = RUR131079, CER2 = RUR94421 and CER3 =
RUR40845 per one patient for group 1, 2, and 3 respectively.
CONCLUSION: Cladribine with interferon alpha usage versus
standard therapy is more cost-effective in the treatment of
patients with hairy cell leukemia.
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OBJECTIVE: Aplastic anemia is a rare disease but its presence
could lead to patient’s death and high expenses for hospitals and
families. The purpose of this study was to model the economic
and health consequences of cyclophosphamide + equine ATG vs.
cyclophosphamide for the management of patients with aplastic
anemia after bone marrow transplantation at the Social Security
Mexican Institute (IMSS). METHODS: A cost-effectiveness
analysis was developed based on a Bayesian decision tree model
from the health care payer’s perspective. Effectiveness measures
were the rate of avoided acute rejected cases without complica-
tions during one-year period and total survival rate on a ﬁve-year
period. Effectiveness data and transition probabilities were taken
from international published literature. Comparators were cyclo-
phosphamide (50 mg/kg) + equine-ATG (30 mg/kg) and cyclo-
phosphamide (50 mg/kg). Resource use was obtained from a
local expert panel at IMSS and direct costs were taken from
ofﬁcial institutional databases. The model was validated and
calibrated according to international pharmacoeconomics guide-
lines. One-way and probabilistic sensitivity analyses were per-
formed using Monte Carlo Simulation second-order approach.
RESULTS: Patients treated with cyclophosphamide + equine
ATG experienced the highest clinical success rate with 17.37%
while patients with monotherapy experienced 2.63% (p < 0.01).
Regarding the 5-year survival rate, the combined therapy
obtained 80.50% vs. cylophosphamide alone 63.40% (p < 0.01).
Expected mean cost per patient with cyclophosphamide + equine
ATG was US$104,773 and US$102,045 for cyclophosphamide.
ICER estimated using the clinical success rate as effectiveness
measure was US$185 and using 5-year survival rate was US$159.
Within probabilistic sensitivity analyses, components analysis
and acceptability curves showed that combined therapy was the
most cost-effective therapy when WTP > US$10,000 (p < 0.05).
CONCLUSION: In Mexico, the combined therapy is cost-
effective for the treatment of aplastic anemia. These results
should be taken into account by Mexican decision makers in the
management of patients with aplastic anemia after bone marrow
transplantation.
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OBJECTIVE: Patients with chronic central neuropathic pain
(CNeP) typically report considerable pain that requires frequent
health care resource (HR) utilisation. The purpose of this study
was to estimate the cost-effectiveness of pregabalin for the man-
agement of CNeP in a Canadian practice setting from a Ministry
of Health perspective. METHODS: A stochastic simulation
model was used to determine the effect of adding pregabalin to
current treatment on daily pain and associated costs in a hypo-
thetical cohort of 1000 patients with chronic CNeP. The model
was based on data from a randomized, double blind, placebo-
controlled, parallel-group, multicentre clinical trial of pregaba-
lin, in which pain was evaluated using a 0–10 pain scale.
Modeled Outcomes of interest included quality-adjusted life-
years (QALYs) and mean number of days with no or mild pain
(score  3) over the trial duration of 12 weeks. HR utilisation
(including drug costs) was assessed from a survey conducted with
a group of 149 Canadian physicians and included number of
physician visits, referral to specialists and waiting times, diag-
nostic tests and non-pharmacological treatments. Corresponding
costs were obtained from Ontario Drug Beneﬁt, London Health
Sciences Centre, and the Régie de l’Assurance Maladie du
Québec, and are expressed in 2007 Canadian dollars. Sensitivity
analyses were conducted on model’s assumptions. RESULTS:
Compared with no additional treatment, treatment with pre-
gabalin yielded a cost-utility ratio of $9648/QALY, and a cost-
effectiveness ratio of $10/day with no or mild pain. Sensitivity
analyses suggested that resulting ratios were very robust to
changes. The most prominent variation reported was for the
extension of the time horizon up to 52 weeks, with a cost-utility
ratio of $23,087/QALY. CONCLUSION: Model simulations
demonstrate that adding pregabalin to the current pharmaco-
therapy received by CNeP patients, compared to no additional
treatment, is a cost-effective treatment strategy.
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COST-EFFECTIVENESS OF PREGABALIN COMPAREDTO
GABAPENTIN INTREATMENT OF PATIENTSWITH
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OBJECTIVE: To estimate the cost-effectiveness of pregaba-
lin compared to gabapentin for patients with postherpetic
neuralgia(PHN) in a Swedish setting. METHODS: This cost-
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